[{"id":"99fd1b20-e5d8-4f4e-b908-4bdb8158c160","acronym":"SIERRA","url":"https://clinicaltrials.gov/study/NCT02665065","created_at":"2021-01-18T12:59:29.161Z","updated_at":"2024-07-02T16:35:42.652Z","phase":"Phase 3","brief_title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT02665065 - SIERRA","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" HLA-DRB1 • PTPRC • HLA-B • HLA-C","pipe":" | ","alterations":" PTPRC expression","tags":["HLA-DRB1 • PTPRC • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTPRC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cytarabine • doxorubicin hydrochloride • azacitidine • cyclophosphamide • Iomab-B (I-131-apamistamab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-07-19"},{"id":"d7248fd6-01ac-49ba-8b6b-ffc926c8dbaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03687099","created_at":"2021-01-18T18:04:32.292Z","updated_at":"2024-07-02T16:36:43.165Z","phase":"","brief_title":"Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma","source_id_and_acronym":"NCT03687099","lead_sponsor":"Centre Hospitalier Universitaire, Amiens","biomarkers":" PTPRC","pipe":" | ","alterations":" PTPRC expression","tags":["PTPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTPRC expression"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 04/30/2018","start_date":" 04/30/2018","primary_txt":" Primary completion: 11/08/2019","primary_completion_date":" 11/08/2019","study_txt":" Completion: 11/08/2019","study_completion_date":" 11/08/2019","last_update_posted":"2020-07-16"}]